Pharmafile Logo
Pharmafocus logo
Advanced Search

hepatitis C

Showing 15 posts of 65 posts found.

gilead-sciences

FDA approves first two antiviral hep C drugs for paediatric patients

April 10, 2017
Sales and Marketing FDA, harvoni, hepatitis C, sovaldi

The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …

News
down_arrow

Hepatitis C market set for slump as cure rates rise

February 14, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing Gilead, hepatitis C

Objectively, it is the pharmaceutical industries intention to find cures for diseases and to aid patients to live a full …

News
abbvie_0

EMA Accelerated Assessment for AbbVie’s hepatitis C regimen

January 24, 2017
Manufacturing and Production, Research and Development AbbVie, EMA, hepatitis C

AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency …

News
abbvie_0

AbbVie investigational hep C drug boasts 97.5% response rate

November 15, 2016
Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic

AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …

News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016
Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …

News
gilead-sciences

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

September 28, 2016
Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …

News
abbvie_0

AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C

AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …

News
gilead-sciences

FDA approves Gilead’s Harvoni in two new indications

February 18, 2016
Research and Development Gilead Sciences, MSD, harvoni, hepatitis C

The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …

News
msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016
Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …

News
Merck image

MSD gets FDA approval for hepatitis C drug Zepatier

January 29, 2016
Medical Communications, Sales and Marketing FDA, MSD, Zepatier, hepatitis C

The competitive hepatitis C market is to get another contender, with FDA approving MSD’s new combo treatment Zepatier (elbasvir and …

News
AbbVie logo

AbbVie tests new hepatitis C drug in Phase III trials

January 11, 2016
Research and Development AbbVie, clinical trials, hepatitis C, phase III

AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …

News
Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

News
Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015
Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

News
Medicines Patent Pool

BMS and Medicines Patent Pool collaborate to increase Hep C medicine access

November 25, 2015
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C

The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …

News
UNITAID

Medicines Patent Pool to include hep C and TB drugs

November 9, 2015
Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis

The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024